Article
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.
Nature medicine - 1 Apr 2017
Davies Helen, Glodzik Dominik, Morganella Sandro, Yates Lucy R, Staaf Johan, Zou Xueqing, Ramakrishna Manasa, Martin Sancha, Boyault Sandrine, Sieuwerts Anieta M, Simpson Peter T, King Tari A, Raine Keiran, Eyfjord Jorunn E, Kong Gu, Borg Åke, Birney Ewan, Stunnenberg Hendrik G, van de Vijver Marc J, Børresen-Dale Anne-Lise, Martens John W M, Span Paul N, Lakhani Sunil R, Vincent-Salomon Anne, Sotiriou Christos, Tutt Andrew, Thompson Alastair M, Van Laere Steven, Richardson Andrea L, Viari Alain, Campbell Peter J, Stratton Michael R, Nik-Zainal Serena
Abstract excerpt
Approximately 1-5% of breast cancers are attributed to inherited mutations in BRCA1 or BRCA2 and are selectively sensitive to poly(ADP-ribose) polymerase (PARP) inhibitors. In other cancer types, germline and/or somatic mutations in BRCA1 and/or BRCA2 (BRCA1/BRCA2) also confer selective sensitivity to PARP inhibitors. Thus, assays to detect BRCA1/BRCA2-deficient tumors have been sought. Recently, somatic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.